Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations

Imagem de Miniatura
Arquivos
art_ANUARDO_Subclinical_Pulmonary_Hypertension_in_Childhood_Systemic_Lupus_Erythematosus_2017.PDF (349.7 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
FERREIRA, Gabriela R. V.
TERRERI, Maria Teresa
Citação
PEDIATRIC CARDIOLOGY, v.38, n.2, p.234-239, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The aim of this study was to evaluate pulmonary hypertension (PH) in 852 childhood-onset systemic lupus erythematosus (cSLE) patients. This was a large multicenter study conducted in 10 Pediatric Rheumatology Services of So Paulo state, Brazil. PH was defined as systolic pulmonary artery pressure > 35 mmHg and/or measurement of the mean pulmonary artery pressure > 25 mmHg and/or diastolic pressure > 15 mmHg by transthoracic echocardiogram. Demographic data, clinical manifestations, disease activity score (SLEDAI-2K), disease damage score (SLICC/ACR-DI) and treatments were also evaluated. Statistical analysis was performed using Bonferroni correction (p < 0.002). PH was observed in 17/852 (2%) cSLE patients. Effort dyspnea occurred in 3/17, chest pain in 1/17 and right ventricle dysfunction in 3/17 cSLE patients. None had pulmonary thromboembolism or antiphospholipid syndrome. Further comparison between 17 cSLE with PH and 85 cSLE control patients without PH with similar disease duration [15 (0-151) vs. 15 (0-153) months, p = 0.448], evaluated at the last visit, revealed higher frequencies of fever (47 vs. 9%, p < 0.001), reticuloendothelial manifestations (41 vs. 7%, p < 0.001) and serositis (35 vs. 5%, p = 0.001) in the former group. Frequencies of renal and neuropsychiatric involvements and antiphospholipid syndrome, as well as the median of SLEDAI-2K and SLICC/ACR-DI scores, were comparable in both groups (p > 0.002). Normal transthoracic echocardiography was evidenced in 9/17 (53%), with median cSLE duration of 17.5 months (1-40) after PH standard treatment. PH was a rare manifestation of cSLE occurring in the first two years of disease. The majority of patients were asymptomatic with mild lupus manifestations. The underlying mechanism seemed not to be related to pulmonary thromboembolism and/or antiphospholipid syndrome.
Palavras-chave
Pulmonary hypertension, Childhood systemic lupus erythematosus, Lung, Multicenter cohort
URI
https://observatorio.fm.usp.br/handle/OPI/19950
Referências
  1. Akdogan A, 2013, JCR-J CLIN RHEUMATOL, V19, P421, DOI 10.1097/RHU.0000000000000037
  2. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes, 1999, ARTHRITIS RHEUM, V42, P599
  3. Avcin T, 2009, LUPUS, V18, P894, DOI 10.1177/0961203309106917
  4. Badesch DB, 2009, J AM COLL CARDIOL, V54, pS55, DOI 10.1016/j.jacc.2009.04.011
  5. Beresford M. W., 2005, Lupus, V14, P152, DOI 10.1191/0961203305lu2073oa
  6. BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185
  7. Ciftci E, 2004, RHEUMATOLOGY, V43, P587, DOI 10.1093/rheumatology/keh120
  8. DELGADO EA, 1990, SEMIN ARTHRITIS RHEU, V19, P285, DOI 10.1016/0049-0172(90)90051-G
  9. Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303
  10. Gladman DD, 2002, J RHEUMATOL, V29, P288
  11. Hassoun PM, 2009, J AM COLL CARDIOL, V54, pS10, DOI 10.1016/j.jacc.2009.04.006
  12. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  13. Huggins JL, 2016, LUPUS, V25, P857, DOI 10.1177/0961203316644339
  14. Johnson SR, 2004, LUPUS, V13, P506, DOI 10.1191/0961203303lu1051oa
  15. Kamel Shereen R, 2011, Clin Med Insights Arthritis Musculoskelet Disord, V4, P77, DOI 10.4137/CMAMD.S7667
  16. Khetarpal R, 1997, SCAND J RHEUMATOL, V26, P325
  17. Koestenberger M, 2016, HEART, V102, P14, DOI 10.1136/heartjnl-2014-307200
  18. Kommireddy S, 2015, RHEUMATOLOGY, V54, P1673, DOI 10.1093/rheumatology/kev097
  19. Leal GN, 2015, LUPUS, V24, P613, DOI 10.1177/0961203314563135
  20. Li M, 2014, LUPUS, V23, P1085, DOI 10.1177/0961203314527366
  21. Perez-Penate GM, 2016, J RHEUMATOL, V43, P323, DOI 10.3899/jrheum.150451
  22. Min HK, 2015, KOREAN J INTERN MED, V30, P232, DOI 10.3904/kjim.2015.30.2.232
  23. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, 2004, PEDIATRICS, V114, P555, DOI 10.1542/PEDS.114.2.S2.555
  24. Nicholson GT, 2013, PEDIATR CARDIOL, V34, P1966, DOI 10.1007/s00246-012-0510-6
  25. Silva CA, 2016, EXPERT REV CLIN IMMU, V12, P301, DOI 10.1586/1744666X.2016.1123621
  26. Takatsuki S, 2011, PEDIATR CARDIOL, V32, P828, DOI 10.1007/s00246-011-9950-7
  27. Veiga CS, 2016, LUPUS, V25, P645, DOI 10.1177/0961203316629554
  28. Ware Dhananjay, 2015, J Assoc Physicians India, V63, P17

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36
Carregar mais